Carlos Rotellar, MD
Nephrology · Bowling Green, KYNPI 1891758439
Payments from drug & device makers
Across 84 payments — averaging $19.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$289
- Otsuka America Pharmaceutical, Inc.$142
- Calliditas Therapeutics US Inc.$126
- Akebia Therapeutics Inc$124
- Vifor Pharma, Inc.$119
- Sanofi$112
- plus $723 from 19 others
What the payments were for
- Food & beverage$1,59297%
- Education$423%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 17 | $289 |
| Otsuka America Pharmaceutical, Inc. | 7 | $142 |
| Calliditas Therapeutics US Inc. | 6 | $126 |
| Akebia Therapeutics Inc | 6 | $124 |
| Vifor Pharma, Inc. | 6 | $119 |
| Sanofi | 6 | $112 |
| Amgen | 5 | $100 |
| Fresenius USA Marketing, Inc. | 5 | $84 |
| Nxstage Medical, Inc. | 3 | $69 |
| Novartis | 3 | $62 |
| Aurinia Pharma U.S., Inc. | 2 | $46 |
| Ardelyx, Inc. | 2 | $40 |
| Shire North American Group Inc | 2 | $34 |
| Daiichi Sankyo Inc. | 2 | $32 |
| Bayer | 2 | $31 |
| Mallinckrodt Enterprises LLC | 1 | $28 |
| Mallinckrodt Hospital Products Inc. | 1 | $27 |
| Travere Therapeutics, Inc. | 1 | $27 |
| Apellis Pharmaceuticals, Inc. | 1 | $26 |
| AMAG Pharmaceuticals, Inc. | 1 | $24 |
| Pharmacosmos Therapeutics Inc. | 1 | $20 |
| Novo Nordisk | 1 | $19 |
| Boehringer Ingelheim | 1 | $19 |
| OPKO Pharmaceuticals, LLC | 1 | $18 |
| Terumo Medical Corporation | 1 | $16 |
How this compares
$1,634 in reported general payments places this provider in the 55th percentile of 165 nephrology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Calcium Acetate | 24 | $986 |
| Potassium Chloride | 11 | $889 |
| Hydralazine Hcl | 25 | $760 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 16 | $207 |
| Metoprolol Succinate | 17 | $171 |
| Furosemide | 27 | $145 |
| Amlodipine Besylate | 18 | $123 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Bowling Green
- Julie IsaacBowling Green$4K
- Jennifer ShuemakerBowling Green$3K
- Dawn CasterLouisville$902K
- Danny WooLouisville$427K
- Boutros El-HaddadLouisville$329K
- Javier Neyra LozanoLexington$223K
- Abdul BuridiLouisville$187K
- Sadiq AhmedLexington$140K
- Kurt SowersHazard$119K
- Nizar AttallahLouisville$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.